<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811224</url>
  </required_header>
  <id_info>
    <org_study_id>15-6644</org_study_id>
    <nct_id>NCT02811224</nct_id>
  </id_info>
  <brief_title>Ovarian Cancer Hemoscope Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, gold standard observational trial designed to enroll consecutive,&#xD;
      consenting ovarian cancer patients for the purpose of determining sensitivity of an assay&#xD;
      that detects circulating tumor DNA. This observational pilot trial will also be used to&#xD;
      examine the genetic variants/mutations present in the tumor tissue DNA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of an assay that detects circulating tumor DNA</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Ovarian Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign Neoplasm</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing surgery as part of the treatment plan for ovarian cancer or a benign&#xD;
        gynecological neoplasm.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Case Group&#xD;
&#xD;
          -  Patients with ovarian cancer undergoing surgery (all stages)&#xD;
&#xD;
          -  Over 18 years old&#xD;
&#xD;
        Control Group&#xD;
&#xD;
          -  Patients with a benign gynecological condition undergoing surgery&#xD;
&#xD;
          -  Over 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous cancer diagnosis (all)&#xD;
&#xD;
          -  Radiation therapy before surgical treatment&#xD;
&#xD;
          -  Bone marrow transplant&#xD;
&#xD;
          -  Chemotherapy before surgical treatment&#xD;
&#xD;
          -  Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal&#xD;
             ablation) in the 7 days prior to baseline (pre-surgical) blood collection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

